Evidence based medicine in the use of botulinum toxin for back pain
Summary Two randomized, prospective studies, one double blind and one open label, longterm evaluated efficacy and safety of Botulinum toxin A (Allergan-Inc) in 31 and 75 patients with chronic low back pain. Both studies used a novel technique imploying 5 level (L1 to L5) injections (40–50 units/leve...
Gespeichert in:
| Veröffentlicht in: | Journal of Neural Transmission 2008-04, Vol.115 (4), p.637-640 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 640 |
|---|---|
| container_issue | 4 |
| container_start_page | 637 |
| container_title | Journal of Neural Transmission |
| container_volume | 115 |
| creator | Jabbari, B. |
| description | Summary
Two randomized, prospective studies, one double blind and one open label, longterm evaluated efficacy and safety of Botulinum toxin A (Allergan-Inc) in 31 and 75 patients with chronic low back pain. Both studies used a novel technique imploying 5 level (L1 to L5) injections (40–50 units/level) of BoNT-A into erector spinae muscles. Significant (
p
< 0.05) improvement of pain intensity, frequency and activities of daily living was noted in 60% and 53% of the patients, respectively. The second study also depicted safety with repeated injections over 14 months of follow up. Botulinum toxin-A should be considered for treatment of low back pain when other modes of treatment fail to improve pain. |
| doi_str_mv | 10.1007/s00702-007-0864-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19887889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1467918101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-66a7318a30fdaa7e7cc68c1d4ffbf2c4bb6bd72ed02eb95202c8f503f820a92b3</originalsourceid><addsrcrecordid>eNqNkUtLxDAUhYMozjj6A9xIcOGuepO0SbqUYXzAgBtdhyRNtGMfY9OK_ntTOjAgCG5uAvc7J-QchM4JXBMAcRPiAJrEmYDkaSIP0JykLEtIytkhmgMDSPKMpzN0EsIGAAgR8hjNiGQZ0FTM0XL1WRausQ4bHVyBa1eUtmwcLhvcvzk8BIdbj03bD1XZDDXu26-48m0XBfYdb3XZnKIjr6vgznbnAr3crZ6XD8n66f5xebtObMpIn3CuBSNSM_CF1sIJa7m0pEi9N57a1BhuCkFdAdSZPKNArfQZMC8p6JwatkBXk--2az8GF3pVl8G6qtKNa4egSC6lkDL_F8gF4RG8_AVu2qFr4icUjUkxkjEZITJBtmtD6JxX266sdfetCKixBzX1oMbr2IMaNRc748HESPeKXfARoBMQ4qp5dd3-5b9dfwD4L5Gw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217831538</pqid></control><display><type>article</type><title>Evidence based medicine in the use of botulinum toxin for back pain</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Jabbari, B.</creator><creatorcontrib>Jabbari, B.</creatorcontrib><description>Summary
Two randomized, prospective studies, one double blind and one open label, longterm evaluated efficacy and safety of Botulinum toxin A (Allergan-Inc) in 31 and 75 patients with chronic low back pain. Both studies used a novel technique imploying 5 level (L1 to L5) injections (40–50 units/level) of BoNT-A into erector spinae muscles. Significant (
p
< 0.05) improvement of pain intensity, frequency and activities of daily living was noted in 60% and 53% of the patients, respectively. The second study also depicted safety with repeated injections over 14 months of follow up. Botulinum toxin-A should be considered for treatment of low back pain when other modes of treatment fail to improve pain.</description><identifier>ISSN: 0300-9564</identifier><identifier>EISSN: 1435-1463</identifier><identifier>DOI: 10.1007/s00702-007-0864-8</identifier><identifier>PMID: 18350247</identifier><identifier>CODEN: JNTRF3</identifier><language>eng</language><publisher>Vienna: Springer-Verlag</publisher><subject>Anti-Dyskinesia Agents - therapeutic use ; Back Pain - drug therapy ; Botulinum Toxins - therapeutic use ; Evidence-Based Medicine ; Humans ; Medicine ; Medicine & Public Health ; Neurology ; Neurosciences ; Pain Measurement ; Psychiatry</subject><ispartof>Journal of Neural Transmission, 2008-04, Vol.115 (4), p.637-640</ispartof><rights>Springer-Verlag 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-66a7318a30fdaa7e7cc68c1d4ffbf2c4bb6bd72ed02eb95202c8f503f820a92b3</citedby><cites>FETCH-LOGICAL-c431t-66a7318a30fdaa7e7cc68c1d4ffbf2c4bb6bd72ed02eb95202c8f503f820a92b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00702-007-0864-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00702-007-0864-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18350247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jabbari, B.</creatorcontrib><title>Evidence based medicine in the use of botulinum toxin for back pain</title><title>Journal of Neural Transmission</title><addtitle>J Neural Transm</addtitle><addtitle>J Neural Transm (Vienna)</addtitle><description>Summary
Two randomized, prospective studies, one double blind and one open label, longterm evaluated efficacy and safety of Botulinum toxin A (Allergan-Inc) in 31 and 75 patients with chronic low back pain. Both studies used a novel technique imploying 5 level (L1 to L5) injections (40–50 units/level) of BoNT-A into erector spinae muscles. Significant (
p
< 0.05) improvement of pain intensity, frequency and activities of daily living was noted in 60% and 53% of the patients, respectively. The second study also depicted safety with repeated injections over 14 months of follow up. Botulinum toxin-A should be considered for treatment of low back pain when other modes of treatment fail to improve pain.</description><subject>Anti-Dyskinesia Agents - therapeutic use</subject><subject>Back Pain - drug therapy</subject><subject>Botulinum Toxins - therapeutic use</subject><subject>Evidence-Based Medicine</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Pain Measurement</subject><subject>Psychiatry</subject><issn>0300-9564</issn><issn>1435-1463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtLxDAUhYMozjj6A9xIcOGuepO0SbqUYXzAgBtdhyRNtGMfY9OK_ntTOjAgCG5uAvc7J-QchM4JXBMAcRPiAJrEmYDkaSIP0JykLEtIytkhmgMDSPKMpzN0EsIGAAgR8hjNiGQZ0FTM0XL1WRausQ4bHVyBa1eUtmwcLhvcvzk8BIdbj03bD1XZDDXu26-48m0XBfYdb3XZnKIjr6vgznbnAr3crZ6XD8n66f5xebtObMpIn3CuBSNSM_CF1sIJa7m0pEi9N57a1BhuCkFdAdSZPKNArfQZMC8p6JwatkBXk--2az8GF3pVl8G6qtKNa4egSC6lkDL_F8gF4RG8_AVu2qFr4icUjUkxkjEZITJBtmtD6JxX266sdfetCKixBzX1oMbr2IMaNRc748HESPeKXfARoBMQ4qp5dd3-5b9dfwD4L5Gw</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Jabbari, B.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20080401</creationdate><title>Evidence based medicine in the use of botulinum toxin for back pain</title><author>Jabbari, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-66a7318a30fdaa7e7cc68c1d4ffbf2c4bb6bd72ed02eb95202c8f503f820a92b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Anti-Dyskinesia Agents - therapeutic use</topic><topic>Back Pain - drug therapy</topic><topic>Botulinum Toxins - therapeutic use</topic><topic>Evidence-Based Medicine</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Pain Measurement</topic><topic>Psychiatry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jabbari, B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of Neural Transmission</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jabbari, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence based medicine in the use of botulinum toxin for back pain</atitle><jtitle>Journal of Neural Transmission</jtitle><stitle>J Neural Transm</stitle><addtitle>J Neural Transm (Vienna)</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>115</volume><issue>4</issue><spage>637</spage><epage>640</epage><pages>637-640</pages><issn>0300-9564</issn><eissn>1435-1463</eissn><coden>JNTRF3</coden><abstract>Summary
Two randomized, prospective studies, one double blind and one open label, longterm evaluated efficacy and safety of Botulinum toxin A (Allergan-Inc) in 31 and 75 patients with chronic low back pain. Both studies used a novel technique imploying 5 level (L1 to L5) injections (40–50 units/level) of BoNT-A into erector spinae muscles. Significant (
p
< 0.05) improvement of pain intensity, frequency and activities of daily living was noted in 60% and 53% of the patients, respectively. The second study also depicted safety with repeated injections over 14 months of follow up. Botulinum toxin-A should be considered for treatment of low back pain when other modes of treatment fail to improve pain.</abstract><cop>Vienna</cop><pub>Springer-Verlag</pub><pmid>18350247</pmid><doi>10.1007/s00702-007-0864-8</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-9564 |
| ispartof | Journal of Neural Transmission, 2008-04, Vol.115 (4), p.637-640 |
| issn | 0300-9564 1435-1463 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19887889 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Anti-Dyskinesia Agents - therapeutic use Back Pain - drug therapy Botulinum Toxins - therapeutic use Evidence-Based Medicine Humans Medicine Medicine & Public Health Neurology Neurosciences Pain Measurement Psychiatry |
| title | Evidence based medicine in the use of botulinum toxin for back pain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T12%3A25%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20based%20medicine%20in%20the%20use%20of%20botulinum%20toxin%20for%20back%20pain&rft.jtitle=Journal%20of%20Neural%20Transmission&rft.au=Jabbari,%20B.&rft.date=2008-04-01&rft.volume=115&rft.issue=4&rft.spage=637&rft.epage=640&rft.pages=637-640&rft.issn=0300-9564&rft.eissn=1435-1463&rft.coden=JNTRF3&rft_id=info:doi/10.1007/s00702-007-0864-8&rft_dat=%3Cproquest_cross%3E1467918101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217831538&rft_id=info:pmid/18350247&rfr_iscdi=true |